サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1668079

二重特異性抗体市場- 世界の産業規模、シェア、動向、機会、予測、適応症別、地域別、競合別、2020～2030年

Bispecific Antibodies Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Indication (Cancer, Inflammatory & Autoimmune Disorders, Others), By Region & Competition, 2020-2030F

出版日
ページ情報
英文 180 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円

こちらのレポートには、数時間（ご購入金額の10%）分のアナリストへの質問／追加調査サービスが含まれております。

二重特異性抗体市場- 世界の産業規模、シェア、動向、機会、予測、適応症別、地域別、競合別、2020～2030年
出版日: 2025年02月28日
発行: TechSci Research
ページ情報: 英文 180 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

二重特異性抗体の世界市場規模は2024年に68億米ドルとなり、予測期間では2030年までCAGR 9.40%で目覚ましい成長が予測されています。

世界の二重特異性抗体市場は、バイオ医薬品業界の大幅な成長と革新を目の当たりにしています。二重特異性抗体は、2つの異なる抗原を同時に標的とするように設計された治療用タンパク質の一種であり、がんや自己免疫疾患など様々な疾患の治療に独自のアプローチを提供します。

市場概要
予測期間 2026～2030年
市場規模：2024年 68億米ドル
市場規模：2030年 116億8,000万米ドル
CAGR：2025～2030年 9.40%
急成長セグメント がん
最大市場 北米

市場促進要因

がんと自己免疫疾患の有病率の上昇

主な市場課題

複雑な設計と製造

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の二重特異性抗体市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • 適応症別（がん、炎症性疾患および自己免疫疾患、その他）
    • 地域別
    • 企業別（2024年）
  • 製品市場マップ
    • 適応症別
    • 地域別

第6章 北米の二重特異性抗体市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 北米：国別分析
    • 米国
    • カナダ
    • メキシコ

第7章 欧州の二重特異性抗体市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 欧州：国別分析
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン

第8章 アジア太平洋地域の二重特異性抗体市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • アジア太平洋地域：国別分析
    • 中国
    • 日本
    • インド
    • オーストラリア
    • 韓国

第9章 南米の二重特異性抗体市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 南米：国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第10章 中東・アフリカの二重特異性抗体市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 中東・アフリカ：国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第11章 市場力学

  • 促進要因
  • 課題

第12章 市場動向と発展

  • 最近の動向
  • 合併と買収
  • 製品上市

第13章 ポーターのファイブフォース分析

  • 業界内の競合
  • 新規参入の可能性
  • サプライヤーの力
  • 顧客の力
  • 代替品の脅威

第14章 競合情勢

  • Amgen Inc
  • F. Hoffmann-La Roche Ltd
  • Genentech Inc
  • Akeso Inc
  • Janssen（Johnson & Johnson Private Limited）
  • Taisho Pharmaceutical Co Ltd
  • Immunocore Ltd

第15章 戦略的提言

第16章 調査会社について・免責事項

目次
Product Code: 17639

Global Bispecific Antibodies Market was valued at USD 6.80 Billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 9.40% through 2030. The global bispecific antibodies market has been witnessing significant growth and innovation in the biopharmaceutical industry. Bispecific antibodies are a class of therapeutic proteins designed to simultaneously target two different antigens, providing a unique approach to treating various diseases, including cancer and autoimmune disorders.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 6.80 Billion
Market Size 2030USD 11.68 Billion
CAGR 2025-20309.40%
Fastest Growing SegmentCancer
Largest MarketNorth America

Key Market Drivers

Rising Prevalence of Cancer and Autoimmune Diseases

The global bispecific antibodies (BsAbs) market is experiencing rapid expansion, primarily driven by the increasing incidence of cancer and autoimmune diseases worldwide. This trend is significantly boosting the demand for innovative, targeted biologics, positioning bispecific antibodies as a key therapeutic solution. In 2022, global cancer statistics revealed significant healthcare and economic challenges, with approximately 20 million new cancer cases diagnosed and 9.7 million cancer-related deaths recorded worldwide. The prevalence of cancer survivors within five years of diagnosis reached 53.5 million, underscoring the growing burden on healthcare systems to provide long-term care and support. Epidemiological data indicates that 1 in 5 individuals will develop cancer during their lifetime, with gender-specific mortality rates highlighting a higher risk among men (1 in 9) compared to women (1 in 12). These figures emphasize the critical need for innovative therapeutic solutions, early detection strategies, and scalable treatment options to address the rising global cancer burden. This rise is attributed to aging populations, lifestyle changes, and environmental factors. The growing cancer burden is increasing demand for advanced, highly effective therapies, which is propelling the adoption of bispecific antibodies in oncology. Unlike traditional monoclonal antibodies (mAbs), bispecific antibodies can simultaneously bind to two different antigens, enhancing tumor cell killing while reducing immune evasion. BsAbs can recruit and activate T cells or NK cells to attack tumor cells, offering a powerful alternative to standard chemotherapy and single-target biologics. Many cancer therapies face resistance over time, but BsAbs help overcome resistance mechanisms by targeting multiple pathways. BsAbs provide a more accessible and cost-effective option compared to personalized CAR-T therapies, which require complex manufacturing processes.

Key Market Challenges

Complex Design and Manufacturing

One of the primary challenges in the bispecific antibodies market is the complexity of their design and manufacturing processes. Creating bispecific antibodies that can simultaneously bind to two distinct molecules or cells requires precise engineering. The intricacies of their structure can lead to manufacturing challenges, impacting scalability, production costs, and consistency in quality.

Key Market Players

  • Amgen Inc
  • F. Hoffmann-La Roche Ltd
  • Genentech Inc
  • Akeso Inc
  • Janssen (Johnson & Johnson Private Limited)
  • Taisho Pharmaceutical Co Ltd
  • Immunocore Ltd

Report Scope:

In this report, the Global Bispecific Antibodies Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Bispecific Antibodies Market, By Indication:

  • Cancer
  • Inflammatory & Autoimmune Disorders
  • Others

Bispecific Antibodies Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Bispecific Antibodies Market.

Available Customizations:

Global Bispecific Antibodies market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Bispecific Antibodies Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Indication (Cancer, Inflammatory & Autoimmune Disorders, Others)
    • 5.2.2. By Region
    • 5.2.3. By Company (2024)
  • 5.3. Product Market Map
    • 5.3.1. By Indication
    • 5.3.2. By Region

6. North America Bispecific Antibodies Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Indication (Cancer, Inflammatory & Autoimmune Disorders, Others)
    • 6.2.2. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Bispecific Antibodies Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Indication
    • 6.3.2. Canada Bispecific Antibodies Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Indication
    • 6.3.3. Mexico Bispecific Antibodies Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Indication

7. Europe Bispecific Antibodies Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Indication (Cancer, Inflammatory & Autoimmune Disorders, Others)
    • 7.2.2. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Bispecific Antibodies Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Indication
    • 7.3.2. United Kingdom Bispecific Antibodies Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Indication
    • 7.3.3. France Bispecific Antibodies Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Indication
    • 7.3.4. Italy Bispecific Antibodies Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Indication
    • 7.3.5. Spain Bispecific Antibodies Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Indication

8. Asia-Pacific Bispecific Antibodies Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Indication (Cancer, Inflammatory & Autoimmune Disorders, Others)
    • 8.2.2. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Bispecific Antibodies Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Indication
    • 8.3.2. Japan Bispecific Antibodies Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Indication
    • 8.3.3. India Bispecific Antibodies Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Indication
    • 8.3.4. Australia Bispecific Antibodies Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Indication
    • 8.3.5. South Korea Bispecific Antibodies Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Indication

9. South America Bispecific Antibodies Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Indication (Cancer, Inflammatory & Autoimmune Disorders, Others)
    • 9.2.2. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Bispecific Antibodies Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Indication
    • 9.3.2. Argentina Bispecific Antibodies Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Indication
    • 9.3.3. Colombia Bispecific Antibodies Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Indication

10. Middle East and Africa Bispecific Antibodies Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Indication (Cancer, Inflammatory & Autoimmune Disorders, Others)
    • 10.2.2. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Bispecific Antibodies Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Indication
    • 10.3.2. Saudi Arabia Bispecific Antibodies Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Indication
    • 10.3.3. UAE Bispecific Antibodies Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Indication
    • 10.3.4. Kuwait Bispecific Antibodies Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Indication

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Product Launches

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Competitive Landscape

  • 14.1. Amgen Inc
    • 14.1.1. Business Overview
    • 14.1.2. Product & Service Offerings
    • 14.1.3. Recent Developments
    • 14.1.4. Financials (If Listed)
    • 14.1.5. Key Personnel
    • 14.1.6. SWOT Analysis
  • 14.2. F. Hoffmann-La Roche Ltd
  • 14.3. Genentech Inc
  • 14.4. Akeso Inc
  • 14.5. Janssen (Johnson & Johnson Private Limited)
  • 14.6. Taisho Pharmaceutical Co Ltd
  • 14.7. Immunocore Ltd

15. Strategic Recommendations

16. About Us & Disclaimer